<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03513601</url>
  </required_header>
  <id_info>
    <org_study_id>hnslblzlzx2017-10</org_study_id>
    <nct_id>NCT03513601</nct_id>
  </id_info>
  <brief_title>Treatment of Elderly Patients With Diffuse Large B-cell Lymphoma</brief_title>
  <official_title>Treatment of Elderly Patients With Diffuse Large B-cell Lymphoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Mingzhi Zhang</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Zhengzhou University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      To explore the clinical features and efficacy evaluation of large b-cell lymphoma in old age.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The results of the analysis of the treatment of large b-cell lymphoma in old age were
      analyzed, and the treatment of large B cell lymphoma was provided.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">July 1, 2017</start_date>
  <completion_date type="Anticipated">May 2019</completion_date>
  <primary_completion_date type="Anticipated">May 2019</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Progression-free survival</measure>
    <time_frame>up to end of follow-up-phase(approximately 24 months)</time_frame>
    <description>Progression-free survival</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>overall survival</measure>
    <time_frame>up to the date of death (approximately 5 years)</time_frame>
    <description>overall survival</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>disease control rate</measure>
    <time_frame>every 6 weeks,up to completion of treatment(approximately 18 weeks )]</time_frame>
    <description>disease control rate</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>objective remission rate</measure>
    <time_frame>every 6 weeks,up to completion of treatment(approximately 18 weeks )]</time_frame>
    <description>objective remission rate</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">20</enrollment>
  <condition>Diffuse Large B Cell Lymphoma</condition>
  <arm_group>
    <arm_group_label>(R)-CHOP regimen</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>(R)-CHOP regimen((rituximab)，cyclophosphamide，epirubicin，vincristine and prednisone)，(rituximab 375mg/m2 d0 ivgtt),cyclophosphamide 750mg/m2 d1、8 ivgtt,epirubicin 50mg/m2 d1、8 ivgtt,vincristine 2mg d1、8 ivgtt,prednisone 60mg d1-5 po.Every 21 days for one cycle and six cycles are required. Efficacy was evaluated every two cycles.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>(R)-CVP regimen</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>(R)-CVP regimen((rituximab)，cyclophosphamide，vincristine and prednisone) The dose of the chemical was reduced by 20%，(rituximab 375mg/m2 d0 ivgtt),cyclophosphamide 750mg/m2 d1、8 ivgtt,vincristine 2mg d1、8 ivgtt,prednisone 60mg d1-5 po.Every 21 days for one cycle and one or two cycles are required. Efficacy was evaluated every two cycles. Subsequent (rituximab 375mg/m2 d0 ivgtt)， oral cyclophosphamide .</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>(R)-CHOP regimen</intervention_name>
    <description>(rituximab 375mg/m2 d0 ivgtt),cyclophosphamide 750mg/m2 d1、8 ivgtt,epirubicin 50mg/m2 d1、8 ivgtt,vincristine 2mg d1、8 ivgtt,prednisone 60mg d1-5 po.Every 21 days for one cycle and six cycles are required. Efficacy was evaluated every two cycles.</description>
    <arm_group_label>(R)-CHOP regimen</arm_group_label>
    <other_name>(rituximab)，CTX，VCR，EPI，PDN</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>(R)-CVP regimen</intervention_name>
    <description>The dose of the chemical was reduced by 20%，(rituximab 375mg/m2 d0 ivgtt),cyclophosphamide 750mg/m2 d1、8 ivgtt,vincristine 2mg d1、8 ivgtt,prednisone 60mg d1-5 po.Every 21 days for one cycle and one or two cycles are required. Efficacy was evaluated every two cycles. Subsequent (rituximab 375mg/m2 d0 ivgtt)， oral cyclophosphamide .</description>
    <arm_group_label>(R)-CVP regimen</arm_group_label>
    <other_name>(rituximab)，CTX，VCR，PDN,20 percent reduction in chemical therapy</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Above 70 years old，Pathology proved to be diffuse large B cell lymphoma，Estimated
             survival time &gt; 3 months，None of chemotherapy contraindication;At least one measurable
             lesion according to RECIST;None of other serious diseases;Patients could be followed
             up;None of other relative treatments including the traditional Chinese medicine,
             immunotherapy,biotherapy except anti-bone metastasis therapy and other symptomatic
             treatments.

        volunteers who signed informed consent.

        Exclusion Criteria:

          -  Currently undergoing chemotherapy, radiotherapy and targeted therapy (received
             chemotherapy within 3 weeks, received radiotherapy within 2 weeks, or has not
             recovered from any previous treatment of acute toxicity);Patients with uncontrolled
             medical problems (including active infection, uncontrolled diabetes, severe heart,
             liver, kidney dysfunction and interstitial pneumonia, etc.); Pregnant or lactating
             women;Serious medical illness likely to interfere with participation;Chemotherapy
             contraindication such as cachexia; patients with other malignancies previously;Serious
             infection;The evidence of peripheral nervous disorder or dysphrenia; patients
             estimated to be unsuitable by investigator.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>70 Years</minimum_age>
    <maximum_age>85 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Mingzhi zhang</last_name>
    <role>Principal Investigator</role>
    <affiliation>The First Affiliated Hospital of Zhengzhou University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Mingzhi zhang, Pro,Dr</last_name>
    <phone>13838565629</phone>
    <email>Mingzhi_zhang@126.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Mingzhi zhang</last_name>
    <phone>13838565629</phone>
    <email>Mingzhi_zhang@126.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Oncology Department of The First Affiliated Hospital of Zhengzhou University</name>
      <address>
        <city>Zhengzhou</city>
        <state>Henan</state>
        <zip>450052</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mingzhi Zhang, Pro,Dr</last_name>
      <phone>13838565629</phone>
      <email>mingzhi_zhang@126.com</email>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>April 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 31, 2017</study_first_submitted>
  <study_first_submitted_qc>April 30, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">May 1, 2018</study_first_posted>
  <last_update_submitted>April 30, 2018</last_update_submitted>
  <last_update_submitted_qc>April 30, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">May 1, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Zhengzhou University</investigator_affiliation>
    <investigator_full_name>Mingzhi Zhang</investigator_full_name>
    <investigator_title>the director of oncology department of the first affiliated hospital</investigator_title>
  </responsible_party>
  <keyword>Curative effect evaluation</keyword>
  <keyword>Adverse reactions</keyword>
  <keyword>Clinical characteristics</keyword>
  <keyword>PR</keyword>
  <keyword>PFS</keyword>
  <keyword>OS</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lymphoma</mesh_term>
    <mesh_term>Lymphoma, B-Cell</mesh_term>
    <mesh_term>Lymphoma, Large B-Cell, Diffuse</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cyclophosphamide</mesh_term>
    <mesh_term>Rituximab</mesh_term>
    <mesh_term>Prednisone</mesh_term>
    <mesh_term>Vincristine</mesh_term>
    <mesh_term>Doxorubicin</mesh_term>
    <mesh_term>Prednisolone</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

